<p>Opthea Limited 未贊助的 ADR (NASDAQ:OPT - 獲取免費報告) 股價在週五上漲了 7.2%。該公司股價最高達到 $3.48，最後交易價為 $3.41。在午盤交易中，交易了 3,000 股。該股票之前收盤價為 $3.18。</p>
<h2>分析師評級變動</h2>
<ul>
<li>如何投資可再生能源</li>
</ul>
<p>另外，Weiss Ratings 在 10 月 14 日的報告中重申了對 Opthea 股票的 &#34;賣出 (d-)&#34; 評級。一位研究分析師給予該股票 &#34;強烈買入&#34; 評級，四位分析師給予 &#34;持有&#34; 評級，另外兩位分析師給予 &#34;賣出&#34; 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 &#34;持有&#34;，共識目標價為 $1.33。</p>
<p><strong>查看我們對 OPT 的最新分析</strong></p>
<h2>Opthea 股價上漲 7.2%</h2>
<p>該公司的 50 日移動平均線為 $3.41，200 日移動平均線也為 $3.41。</p>
<h2>機構投資者對 Opthea 的看法</h2>
<p>大型投資者最近對該公司的持倉進行了調整。EP Wealth Advisors LLC 在第一季度購買了 Opthea 的新股份，價值約 $34,000。OLD Mission Capital LLC 在第一季度將其在 Opthea 的持倉增加了 78.7%。OLD Mission Capital LLC 現在擁有 19,167 股該公司的股票，價值 $65,000，此前在該期間又購買了 8,439 股。Twin Lakes Capital Management LLC 在第一季度將其在 Opthea 的持倉增加了 67.4%。Twin Lakes Capital Management LLC 現在擁有 33,156 股該公司的股票，價值 $113,000，此前在該期間又購買了 13,350 股。最後，Regal Partners Ltd 在第一季度將其在 Opthea 的持倉增加了 78.6%。Regal Partners Ltd 現在擁有 5,193,688 股該公司的股票，價值 $17,710,000，此前在該期間又購買了 2,286,285 股。機構投資者持有該公司 55.95% 的股票。</p>
<h2>關於 Opthea</h2>
<p>(獲取免費報告)</p>
<p>Opthea Limited 是一家臨牀階段的生物製藥公司，專注於在澳大利亞開發和商業化主要用於眼病的治療。該公司的開發活動基於涵蓋血管內皮生長因子 (VEGF) VEGF-C、VEGF-D 和 VEGF 受體-3 的知識產權組合，用於治療與血管和淋巴管生長以及血管滲漏相關的疾病。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票比 Opthea 更好</li>
<li>如何購買黃金股票並投資黃金</li>
<li>Rayonier-PotlatchDeltic 合併預示行業上行</li>
<li>為什麼這些公司被視為藍籌股？</li>
<li>Hims &amp; Hers 空頭頭寸接近歷史高點，是否應該買入？</li>
<li>如何計算期權利潤</li>
<li>這隻防禦性股票有 $570 億的訂單積壓和新的 AI 發展機遇</li>
</ul>
<p><em>此即時新聞提醒是由敍述科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 $1,000 在 Opthea 嗎？</h2>
<p>在你考慮 Opthea 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Opthea 並不在名單上。</p>
<p>雖然 Opthea 目前在分析師中獲得了 &#34;持有&#34; 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

OPTEY

<p>Opthea Limited（納斯達克代碼：OPT）週五股價上漲 7.2%，至 3.41 美元，較前一交易日的 3.18 美元有所上升。分析師評級顯示一項強烈買入、四項持有和兩項賣出評級，市場共識目標價為 1.33 美元。機構投資者持有該股票的 55.95%，多家公司的持股顯著增加。Opthea 專注於在澳大利亞開發眼病治療方案，利用其在血管內皮生長因子（VEGF）方面的知識產權</p>

<p>Opthea Limited Unsponsored ADR (NASDAQ:OPT - Get Free Report) shares traded up 7.2% on Friday . The company traded as high as $3.48 and last traded at $3.41. 3,000 shares traded hands during mid-day trading, The stock had previously closed at $3.18.</p>
<div class="lb-trans"><p>Opthea Limited 未贊助的 ADR (NASDAQ:OPT - 獲取免費報告) 股價在週五上漲了 7.2%。該公司股價最高達到 $3.48，最後交易價為 $3.41。在午盤交易中，交易了 3,000 股。該股票之前收盤價為 $3.18。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>How to Invest in Renewable Energy</li>
</ul>
<div class="lb-trans"><ul>
<li>如何投資可再生能源</li>
</ul>
</div><p>Separately, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Opthea in a report on Tuesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $1.33.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 10 月 14 日的報告中重申了對 Opthea 股票的 &#34;賣出 (d-)&#34; 評級。一位研究分析師給予該股票 &#34;強烈買入&#34; 評級，四位分析師給予 &#34;持有&#34; 評級，另外兩位分析師給予 &#34;賣出&#34; 評級。根據 MarketBeat.com 的數據，該公司的共識評級為 &#34;持有&#34;，共識目標價為 $1.33。</p>
</div><p><strong>View Our Latest Analysis on OPT</strong></p>
<div class="lb-trans"><p><strong>查看我們對 OPT 的最新分析</strong></p>
</div><h2>Opthea Stock Up 7.2%</h2>
<div class="lb-trans"><h2>Opthea 股價上漲 7.2%</h2>
</div><p>The company has a 50 day moving average of $3.41 and a 200 day moving average of $3.41.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 $3.41，200 日移動平均線也為 $3.41。</p>
</div><h2>Institutional Investors Weigh In On Opthea</h2>
<div class="lb-trans"><h2>機構投資者對 Opthea 的看法</h2>
</div><p>Large investors have recently made changes to their positions in the company. EP Wealth Advisors LLC bought a new stake in shares of Opthea in the 1st quarter valued at approximately $34,000. OLD Mission Capital LLC boosted its position in Opthea by 78.7% during the first quarter. OLD Mission Capital LLC now owns 19,167 shares of the company's stock worth $65,000 after purchasing an additional 8,439 shares during the period. Twin Lakes Capital Management LLC boosted its position in Opthea by 67.4% during the first quarter. Twin Lakes Capital Management LLC now owns 33,156 shares of the company's stock worth $113,000 after purchasing an additional 13,350 shares during the period. Finally, Regal Partners Ltd boosted its position in Opthea by 78.6% during the first quarter. Regal Partners Ltd now owns 5,193,688 shares of the company's stock worth $17,710,000 after purchasing an additional 2,286,285 shares during the period. Institutional investors own 55.95% of the company's stock.</p>
<div class="lb-trans"><p>大型投資者最近對該公司的持倉進行了調整。EP Wealth Advisors LLC 在第一季度購買了 Opthea 的新股份，價值約 $34,000。OLD Mission Capital LLC 在第一季度將其在 Opthea 的持倉增加了 78.7%。OLD Mission Capital LLC 現在擁有 19,167 股該公司的股票，價值 $65,000，此前在該期間又購買了 8,439 股。Twin Lakes Capital Management LLC 在第一季度將其在 Opthea 的持倉增加了 67.4%。Twin Lakes Capital Management LLC 現在擁有 33,156 股該公司的股票，價值 $113,000，此前在該期間又購買了 13,350 股。最後，Regal Partners Ltd 在第一季度將其在 Opthea 的持倉增加了 78.6%。Regal Partners Ltd 現在擁有 5,193,688 股該公司的股票，價值 $17,710,000，此前在該期間又購買了 2,286,285 股。機構投資者持有該公司 55.95% 的股票。</p>
</div><h2>About Opthea</h2>
<div class="lb-trans"><h2>關於 Opthea</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.</p>
<div class="lb-trans"><p>Opthea Limited 是一家臨牀階段的生物製藥公司，專注於在澳大利亞開發和商業化主要用於眼病的治療。該公司的開發活動基於涵蓋血管內皮生長因子 (VEGF) VEGF-C、VEGF-D 和 VEGF 受體-3 的知識產權組合，用於治療與血管和淋巴管生長以及血管滲漏相關的疾病。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Opthea</li>
<li>How to Buy Gold Stock and Invest in Gold</li>
<li>Rayonier-PotlatchDeltic Merger Signals Industry Upside</li>
<li>Why Are These Companies Considered Blue Chips?</li>
<li>Hims &amp; Hers Short Interest Nears All-Time High, Buy The Dip?</li>
<li>How to Calculate Options Profits</li>
<li>This Defense Stock Has a $57B Backlog and New AI Tailwinds</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票比 Opthea 更好</li>
<li>如何購買黃金股票並投資黃金</li>
<li>Rayonier-PotlatchDeltic 合併預示行業上行</li>
<li>為什麼這些公司被視為藍籌股？</li>
<li>Hims &amp; Hers 空頭頭寸接近歷史高點，是否應該買入？</li>
<li>如何計算期權利潤</li>
<li>這隻防禦性股票有 $570 億的訂單積壓和新的 AI 發展機遇</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒是由敍述科學技術和 MarketBeat 的金融數據生成的，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送郵件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Opthea Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 $1,000 在 Opthea 嗎？</h2>
</div><p>Before you consider Opthea, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Opthea 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opthea wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前買入……而 Opthea 並不在名單上。</p>
</div><p>While Opthea currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Opthea 目前在分析師中獲得了 &#34;持有&#34; 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Opthea（NASDAQ:OPT）股價上漲 7.2% - 以下是原因